Literature DB >> 21163887

High frequency of TTK mutations in microsatellite-unstable colorectal cancer and evaluation of their effect on spindle assembly checkpoint.

Iina Niittymäki1, Alexandra Gylfe, Leena Laine, Marko Laakso, Heli J Lehtonen, Johanna Kondelin, Jaana Tolvanen, Kari Nousiainen, Jeroen Pouwels, Heikki Järvinen, Kyösti Nuorva, Jukka-Pekka Mecklin, Markus Mäkinen, Ari Ristimäki, Torben F Ørntoft, Sampsa Hautaniemi, Auli Karhu, Marko J Kallio, Lauri A Aaltonen.   

Abstract

Frameshift mutations frequently accumulate in microsatellite-unstable colorectal cancers (MSI CRCs) typically leading to downregulation of the target genes due to nonsense-mediated messenger RNA decay. However, frameshift mutations that occur in the 3' end of the coding regions can escape decay, which has largely been ignored in previous works. In this study, we characterized nonsense-mediated decay-escaping frameshift mutations in MSI CRC in an unbiased, genome wide manner. Combining bioinformatic search with expression profiling, we identified genes that were predicted to escape decay after a deletion in a microsatellite repeat. These repeats, located in 258 genes, were initially sequenced in 30 MSI CRC samples. The mitotic checkpoint kinase TTK was found to harbor decay-escaping heterozygous mutations in exon 22 in 59% (105/179) of MSI CRCs, which is notably more than previously reported. Additional novel deletions were found in exon 5, raising the mutation frequency to 66%. The exon 22 of TTK contains an A(9)-G(4)-A(7) locus, in which the most common mutation was a mononucleotide deletion in the A(9) (c.2560delA). When compared with identical non-coding repeats, TTK was found to be mutated significantly more often than expected without selective advantage. Since TTK inhibition is known to induce override of the mitotic spindle assembly checkpoint (SAC), we challenged mutated cancer cells with the microtubule-stabilizing drug paclitaxel. No evidence of checkpoint weakening was observed. As a conclusion, heterozygous TTK mutations occur at a high frequency in MSI CRCs. Unexpectedly, the plausible selective advantage in tumourigenesis does not appear to be related to SAC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21163887     DOI: 10.1093/carcin/bgq272

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

1.  TC Mps1 12, a novel Mps1 inhibitor, suppresses the growth of hepatocellular carcinoma cells via the accumulation of chromosomal instability.

Authors:  Minji Choi; Yoo Hong Min; Jaehyuk Pyo; Chang-Woo Lee; Chang-Young Jang; Ja-Eun Kim
Journal:  Br J Pharmacol       Date:  2017-04-22       Impact factor: 8.739

Review 2.  The MPS1 family of protein kinases.

Authors:  Xuedong Liu; Mark Winey
Journal:  Annu Rev Biochem       Date:  2012-04-05       Impact factor: 23.643

3.  Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma.

Authors:  Xiao-Dong Liang; Yue-Chu Dai; Zhao-Yun Li; Mei-Fu Gan; Shi-Rong Zhang; Hong-Sheng Lu; Xue-Quan Cao; Bei-jia Zheng; Ling-Fen Bao; Dan-Dan Wang; Li-Ming Zhang; Sheng-Lin Ma
Journal:  PLoS One       Date:  2014-06-06       Impact factor: 3.240

4.  Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post-chemotherapy tissues.

Authors:  Mengsha Tong; Weicheng Zheng; Xingrong Lu; Lu Ao; Xiangyu Li; Qingzhou Guan; Hao Cai; Mengyao Li; Haidan Yan; You Guo; Pan Chi; Zheng Guo
Journal:  Oncotarget       Date:  2015-12-01

5.  Expression of Cancer Testis Antigens in Colorectal Cancer: New Prognostic and Therapeutic Implications.

Authors:  Maciej Tarnowski; Michał Czerewaty; Anna Deskur; Krzysztof Safranow; Wojciech Marlicz; Elżbieta Urasińska; Mariusz Z Ratajczak; Teresa Starzyńska
Journal:  Dis Markers       Date:  2016-08-18       Impact factor: 3.434

6.  Investigating core genetic-and-epigenetic cell cycle networks for stemness and carcinogenic mechanisms, and cancer drug design using big database mining and genome-wide next-generation sequencing data.

Authors:  Cheng-Wei Li; Bor-Sen Chen
Journal:  Cell Cycle       Date:  2016-06-13       Impact factor: 4.534

7.  TTK promotes mesenchymal signaling via multiple mechanisms in triple negative breast cancer.

Authors:  Jamie L King; Baotong Zhang; Yixiang Li; Kathy P Li; Jianping J Ni; Harold I Saavedra; Jin-Tang Dong
Journal:  Oncogenesis       Date:  2018-09-12       Impact factor: 7.485

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.